Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240182 | 0.86 | NCF1 (0.53) | NCF1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3242381 | 0.85 | NCF1 (0.51) | NCF1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL8965571 | 0.79 | PRMT6 (0.51) | NCF1PRMT6SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL8088260 | 0.79 | PRMT6 (0.51) | NCF1PRMT6SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL8088259 | 0.79 | PRMT6 (0.51) | NCF1PRMT6SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3245819 | 0.77 | CHKA (0.53) | NCF1PRMT6KDM4E | |
| SCHEMBL4547888 | 0.75 | PRMT6 (0.57) | PRMT6SMN1; SMN2ALDH1A1TDP1KDM4E | |
| SCHEMBL27046169 | 0.74 | PRMT6 (0.47) | PRMT6SMN1; SMN2ALDH1A1TDP1KDM4E | |
| SCHEMBL1619365 | 0.74 | SMN1; SMN2 (0.58) | PRMT6SMN1; SMN2ALDH1A1TDP1KDM4E | |
| SCHEMBL1935413 | 0.73 | PRMT6 (0.58) | PRMT6SMN1; SMN2ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | CASR 1729/4885NCF1 1244/4885PRMT6 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.